Truist analyst Danielle Brill initiated coverage of BridgeBio (BBIO) with a Buy rating and $66 price target The Attruby launch in transthyretin amyloidosis appears to be off to a strong start and should continue to beat expectations, the analyst tells investors in a research note. The firm projects the ATTR-CM market to grow to roughly $20B, and sees unrealized value for Attruby.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs
- BridgeBio Pharma’s Promising Diversification and High-Margin Opportunities Drive Buy Rating
- Rivian downgraded, PayPal upgraded: Wall Street’s top analyst calls
- BridgeBio price target raised to $56 from $53 at Leerink
- BridgeBio price target raised to $68 from $63 at Piper Sandler